Is erlotinib better or gefitinib

Erlotinib: squamous cell carcinoma, male.

Gefitinib: adenocarcinoma, female.

Han Xiu**.

1. Gefitinib: Gefitinib (Gefitinib, Iricco, Iressa) is an oral epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitor (small molecule compound). Suppression of EGFR-TK can hinder tumor growth, metastasis, and angiogenesis, and increase apoptosis of tumor cells.

It is the first generation of non-small cell lung cancer inhibitory target drugs.

2. Afatinib: Afatinib is a potent and irreversible dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) tyrosine kinase. This drug is mainly indicated for locally advanced or transmitive mobile non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) gene sensitive mutations, and locally advanced or metastatic squamous tissue type of non-small cell lung cancer (NSCLC) that has not previously received EGFR tyrosine kinase inhibitor (TKI)**2 disease progression during or after chemotherapy-containing chemotherapy.

It is a second-generation non-small cell lung cancer inhibitory targeted drug.

First do target type detection, and select the corresponding targeted drugs according to the target type, gefitinib and erlotinib belong to the first generation of targeted drugs, and afatinib belongs to the second generation of targeted drugs. Priority is given to the first generation of targeted drugs, and the same is a first-generation targeted drug, and if applicable, the more affordable gefitinib is preferred.

About this.

Gefitinib is mainly rash, nausea, vomiting, and diarrhea, but it is generally very small and can be tolerated.

This has a suitable target.

Taiyi, monk's name. After Buddhism became popular in China, it specifically referred to male monks who became monks according to the precepts, meaning the same as monks.

Just, to. Lushan is far away, referring to Huiyuan.

According to the Jin Dynasty's "Lotus Society Gaoxian Biography" records: the Jin Dynasty monk Huiyuan, into the Lushan to live in Donglin Temple to practice, known as "Yuan Gong". It was famous in the Tang Dynasty and was mostly seen in Tang poetry. For example, Meng Haoran "tasted the distant public biography and forever cherished the traces of the dust".

Evening Park Xunyang Wanglu Mountain") and so on.

Hello. *** in this regard.

It is usually a rash and diarrhea.

So it is also necessary to deal with the follow-up reaction.

At present, there are other good targeted drugs.

For example, [Liu Ye's insistence]!

Listen to the doctor's opinion, there are people here who use the medicine.

It varies from person to person, and it can disappear on its own after a few days.

Gefitinib has a rapid onset of action, with an average of 8 to 10 days of medication leading to symptom relief. If effective, most of them can be seen after 1 month of medication. Rash is a common adverse reaction, and it should be noted that it should not be cleaned with alkaline chemical daily necessities, such as soap, etc., and only with water.

**When there is a ulcer or pustule, it is necessary to pay attention to avoid infection, and if necessary, please ask the doctor to deal with it. Asymptomatic moderate aminotransferase elevations do not require discontinuation, and some patients recover spontaneously. However, if there is a moderate elevation of aminotransferases, it is best to stop the drug and wait until recovery before resuming the drug.

This product is suitable for locally advanced or metastatic non-small cell lung cancer (NSCLC) that has received chemical treatment before. Previous chemistry** mainly refers to platinum and docetaxel**. The efficacy of this product in patients with locally advanced or metastatic non-small cell lung cancer who have previously received chemical ** is based on the survival advantage of the Asian subgroup presupposed in a large-scale placebo-controlled clinical trial (Note:

The trial did not show improvement in disease-related symptoms or prolonged survival in the overall population) and survival data from uncontrolled clinical trials in China. Results from two large randomized controlled trials have shown that gefitinib in combination with platinum-based chemotherapy has not shown clinical benefit in first-line** locally advanced or metastatic NSCLC, so such combinations are not recommended.